ClinicalTrials.gg

Program

emraclidine

Also written as “Emraclidine”, “CVL-231” and “Emraclidine 30 mg”.

In AbbVie's pipeline, M4 PAM. Its studies are mostly in Schizophrenia · Alzheimer Disease · Renal Insufficiency, led by 2 companies.

Furthest: phase 2, since Jan 27, 202218 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie172 open or runningphase 2since Jan 27, 2022Oct 16, 2019Dec 2026phase 1 · NCT07219030
Pfizer10 open or runningphase 1since Jul 6, 2017Jul 6, 2017none ahead
  • Named in AbbVie’s own pipeline as Emraclidine, phase 2, as of Jul 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Jul 6, 2017.

  1. Oct 16, 2019AbbVie's first study: phase 1 study in SchizophreniaNew to AbbVieAbbVie · NCT04136873 · 130 enrolled · United States
  2. Feb 1, 2021Phase 1 study in SchizophreniaAbbVie · NCT04787302 · 15 enrolled · United States, Belgium
  3. Nov 1, 2021Phase 1 study in SchizophreniaAbbVie · NCT05106309 · 16 enrolled · United States
  4. Jan 27, 2022Phase 1 study in SchizophreniaAbbVie · NCT05245539 · 151 enrolled · United States
  5. Jan 27, 20222 phase 2 studies in SchizophreniaAbbVie · NCT05227703, NCT05227690
  6. Jun 29, 2022Phase 2 study in SchizophreniaAbbVie · NCT05443724 · 698 enrolled · United States, Bulgaria, Hungary and more
  7. Dec 1, 2022Phase 1 study in Healthy ParticipantsAbbVie · NCT05644977 · 17 enrolled · United States
  8. Jun 13, 20233 phase 1 studiesAbbVie · NCT05915546, NCT05933187, NCT05935033
  9. Jul 2, 2023Phase 1 study in Renal InsufficiencyAbbVie · NCT05940402 · 58 enrolled · United States
  10. Mar 1, 2024Phase 1 study in Healthy ParticipantsAbbVie · NCT06301971 · 8 enrolled · United States
  11. Apr 11, 2024Phase 1 study in Healthy ParticipantsAbbVie · NCT06366243 · 20 enrolled · United States
  12. Aug 22, 2025Phase 2 study in SchizophreniaAbbVie · NCT07145918 · 268 planned · United States
  13. Oct 17, 2025Phase 1 study in Healthy VolunteerAbbVie · NCT07219030 · 52 planned · United States
  14. May 8, 2026Phase 1 study in Healthy VolunteersAbbVie · NCT07587008 · 12 enrolled · United States

Ahead

  1. Dec 2026Primary completion: phase 1 study in Healthy VolunteerAbbVie · NCT07219030
  2. Feb 2028Primary completion: phase 2 study in SchizophreniaAbbVie · NCT07145918

TargetBeta

“M4 PAM”the company's pipeline, read by Claude · source

Other programs on CHRM4

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487
xanomelineruleBristol-Myers Squibbphase 438
GXV-813Novartisphase 21
ABBV-1042AbbViephase 11
BMS-986521Bristol-Myers Squibbphase 11

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07587008Healthy Volunteers · United States1CompletedAbbVieJul 17, 202612
NCT07219030Healthy Volunteer · United States1RecruitingAbbVieDec 202652
NCT07145918Schizophrenia · United States2RecruitingAbbVieFeb 2028268
NCT06366243Healthy Participants · United States1CompletedAbbVieJun 20, 202420
NCT06301971Healthy Participants · United States1CompletedAbbVieApr 4, 20248
NCT05940402Renal Insufficiency · United States1CompletedAbbVieDec 19, 202458
NCT05935033Hepatic Impairment · United States1CompletedAbbVieFeb 21, 202538
NCT05933187Healthy Participants · United States1CompletedAbbVieSep 12, 202315
NCT05915546Healthy · United States1CompletedAbbVieJul 26, 202316
NCT05644977Healthy Participants · United States1CompletedAbbVieApr 14, 202517
NCT05443724Schizophrenia · United States, Bulgaria, Hungary and more2TerminatedAbbVieJun 25, 2025698
NCT05245539Schizophrenia · United States1CompletedAbbVieOct 19, 2022151
NCT05227703Schizophrenia · United States, Bulgaria, Hungary2CompletedAbbVieAug 15, 2024391
NCT05227690Schizophrenia · United States, Bulgaria2CompletedAbbVieAug 23, 2024385
NCT05106309Schizophrenia · United States1CompletedAbbVieFeb 24, 202216
NCT04787302Schizophrenia · United States, Belgium1CompletedAbbVieJul 14, 202315
NCT04136873Schizophrenia · United States1CompletedAbbVieMay 7, 2021130
NCT03217604Healthy Volunteers · Belgium1CompletedPfizerFeb 1, 201817

How it is read

Names in the registry

  • “Emraclidine”, 9 entries
  • “CVL-231”, 5 entries
  • “Emraclidine 30 mg”, 3 entries
  • “Emraclidine 15 mg”, 1 entry
  • “Emraclidine 10 mg”, 1 entry

Codes read as this program: CVL231.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.